The impact of genetic variations in retinoid X receptor alpha on the risk and prognosis of HPV‐negative oral carcinoma
European Journal of Oral Sciences · 2025
DOI: 10.1111/eos.70015 ↗At a glance
Journal article in European Journal of Oral Sciences, 2025. Written by Dragan Pandzic and 9 co-authors. Institution: Department for Maxillofacial Surgery, University Clinical Center of the Republika Srpska, Banja Luka, Bosnia and Herzegovina. Major MEDLINE topics: Mouth Neoplasms, Retinoid X Receptor alpha, Carcinoma, Squamous Cell. 66 references. Funded by: Medical Faculty of the Military Medical Academy, University of Defense, Belgrade, Serbia.
Abstract (original language)
Oral squamous cell carcinoma (OSCC) is characterized by a high recurrence rate and poor survival. The retinoid X receptor (RXR) is a nuclear receptor that modulates a variety of biological processes related to cancer, including apoptosis, cellular adhesion, and immune function. A number of cancers exhibit aberrant expression and altered function of the RXR isoform alpha (RXRA), but the polymorphisms in the RXRA gene have not been investigated previously in patients with oral cancer. The current study examined the RXRA rs7864987 and rs3118523 genetic variants, assessed by the real‐time PCR Taq‐Man method, in 95 HPV‐negative OSCC patients and 101 age‐ and sex‐matched healthy controls. Kaplan‐Meier analysis revealed that RXRA rs7864987 was significantly associated with worse overall survival and showed a tendency toward lower recurrence‐free survival when compared with the wild‐type allele carriers (combined TC+TT genotypes) to the mutant genotype CC. RXRA rs7864987, however, did not independently predict overall survival. The C allele of the RXRA rs3118523 genetic variant was associated with a reduced risk of OSCC. Our study indicates that polymorphisms of the RXRA gene may be prognostic and disease‐predisposing genetic factors for OSCC. Additionally, RXRA polymorphisms might influence a potential genetic profile‐based approach for retinoid therapy in OSCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department for Maxillofacial Surgery, University Clinical Center of the Republika Srpska, Banja Luka, Bosnia and Herzegovina.
- Medical Faculty of Military Medical Academy, University of Defense, Belgrade, Serbia.
- Institute for Medical Research, Military Medical Academy, Belgrade, Serbia.
- Clinic for Maxillofacial Surgery, Military Medical Academy, Belgrade, Serbia.
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
- Institute for Anatomy, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
ORCID profiles: Dragan Pandzic, Gordana Supic, Debora Misic, Aleksandra Petkovic Curcin, Sasa Jovic, Zoran Kozomara, Katarina Djurdjevic, Srboljub Stosic, Ruzica Kozomara
Funding
- Medical Faculty of the Military Medical Academy, University of Defense, Belgrade, Serbia
Cite
APA
Pandzic, D., Supic, G., Misic, D., Curcin, A. P., Jovic, S., Brkic, M., Kozomara, Z., Djurdjevic, K., Stosic, S., & Kozomara, R. (2025). The impact of genetic variations in retinoid X receptor alpha on the risk and prognosis of HPV‐negative oral carcinoma. European Journal of Oral Sciences. https://doi.org/10.1111/eos.70015
Vancouver
Pandzic D, Supic G, Misic D, Curcin AP, Jovic S, Brkic M, et al. The impact of genetic variations in retinoid X receptor alpha on the risk and prognosis of HPV‐negative oral carcinoma. European Journal of Oral Sciences. 2025. doi:10.1111/eos.70015
BibTeX
@article{Pandzic2025,
author = {Pandzic, Dragan and Supic, Gordana and Misic, Debora and Curcin, Aleksandra Petkovic and Jovic, Sasa and Brkic, Marko and Kozomara, Zoran and Djurdjevic, Katarina and Stosic, Srboljub and Kozomara, Ruzica},
title = {The impact of genetic variations in retinoid X receptor alpha on the risk and prognosis of HPV‐negative oral carcinoma},
journal = {European Journal of Oral Sciences},
year = {2025},
doi = {10.1111/eos.70015}
}
EUVIMED